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Therapeutic targeting of HMGB1 
during experimental sepsis 
modulates the inflammatory 
cytokine profile to one associated 
with improved clinical outcomes
Natalie E. Stevens1, Marianne J. Chapman2,3, Cara K. Fraser4, Tim R. Kuchel4, John D. 
Hayball1,5 & Kerrilyn R. Diener  1,5
Sepsis remains a significant health burden and a major clinical need exists for therapeutics to dampen 
the excessive and uncontrolled immune activation. Nuclear protein high mobility group box protein 1 
(HMGB1) is released following cell death and is a late mediator in sepsis pathogenesis. While approaches 
targeting HMGB1 have demonstrated reduced mortality in pre-clinical models of sepsis, the impact 
of HMGB1 blockade on the complex septic inflammatory milieu and the development of subsequent 
immunosuppression remain enigmatic. Analysis of plasma samples obtained from septic shock patients 
established an association between increased HMGB1 and non-survival, higher APACHE II scores, and 
increased pro-inflammatory cytokine responses. Pre-clinically, administration of neutralising ovine 
anti-HMGB1 polyclonal antibodies improved survival in murine endotoxaemia and caecal ligation 
and puncture-induced sepsis models, and altered early cytokine profiles to one which corresponded 
to patterns observed in the surviving patient cohort. Additionally, anti-HMGB1 treated murine sepsis 
survivors were significantly more resistant to secondary bacterial infection and exhibited altered 
innate immune cell phenotypes and cytokine responses. These findings demonstrate that anti-HMGB1 
antibodies alter inflammation in murine sepsis models and reduce sepsis mortality without potentiating 
immunosuppression.
Sepsis is characterised by an exacerbated inflammatory response following infection that damages host organs1. 
Once considered a syndrome of excessive inflammation, sepsis is now recognized as a syndrome of dysregu-
lated immune function2, 3. While improved treatment paradigms have increased short-term survival from sep-
sis, an increased number of patients now experience prolonged immunosuppression which often culminates in 
long-term morbidity and mortality4. Consequently, novel treatment strategies should not only aim to increase 
short-term survival by controlling the acute inflammatory phase of disease, but also prevent long-term disability 
by restoring immune balance and function.
While dysregulated expression of the cytokines interleukin 6 (IL-6)5, tumour necrosis factor alpha (TNFα), 
IL-1 and IL-86 has been associated with sepsis mortality, no therapeutic intervention targeting an individual 
cytokine has conferred significant benefit above standard monitoring and supportive care. A meta-analysis 
of TNFα-targeted therapies revealed only a 2% improvement to mortality compared to placebo7. Similarly, 
IL-1 receptor agonist (IL-1RA) administration exhibited limited clinical success8. The failure of such mon-
otherapies has been linked to the timing of administration as expression of these cytokines mainly occurs 
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during the ‘early-phase’ of disease, and therefore treatment may have been initiated too late. Administration 
of anti-inflammatory IL-10 has shown promise in reducing morbidity in preclinical sepsis models9, however 
additional IL-10 may promote secondary infection, as IL-10 has also been associated with post-septic immuno-
suppression10. Thus approaches targeting ‘late-phase’ mediators or master regulators of inflammation may hold 
more therapeutic promise.
Nuclear protein high mobility group box 1 (HMGB1) has emerged as a key inflammatory mediator that is 
released during sepsis by activated immune cells and necrotic tissue where it functions as a damage-associated 
molecular pattern (DAMP)11. Extracellular HMGB1 interacts with toll-like receptor 4 (TLR4) and the receptor 
for advanced glycation endproducts (RAGE) to promote chemotaxis and NF-κB signalling. Therapies targeting 
HMGB1 via molecular inhibitors12 or upstream inhibition13 has been shown to reduce mortality in sepsis models, 
and has a wide therapeutic window14, 15. Extracellular HMGB1 exists in various structural arrangements depend-
ant on release11; for instance necrosis triggers extracellular release of DNA-bound HMGB116, whilst apoptotic 
cells release HMGB1-containing vesicles17. Once in the extracellular space, HMGB1 readily forms complexes with 
different chemokines, cytokines and bacterial components to instigate differential downstream effects.
Importantly, HMGB1 has been implicated in post-septic immunosuppression through varying redox states of 
three cysteine residues within the full-length protein. While disulphide HMGB1 exerts pro-inflammatory effects 
through TLR4 and RAGE18, terminally oxidised HMGB1 has roles in the resolution of immune responses, tissue 
regeneration18–20 and the induction of tolerance21, 22. In the context of sepsis, HMGB1 may function as a biologi-
cal ‘switch’ to instigate inflammation resolution and potentially drive immune dysregulation following the acute 
pro-inflammatory phase. Consequently, a passive immunotherapy approach using anti-HMGB1 polyclonal anti-
bodies may confer additional benefits over that observed with monoclonal therapies by their ability to neutralise 
multiple epitopes on different HMGB1 forms, thus inhibiting several DAMP-associated functions of HMGB1 at 
once.
Results
Elevated plasma HMGB1 is associated with morbidity and mortality in a cohort of septic shock 
patients. Previous studies have demonstrated elevated HMGB1 in patients currently with, or recovered 
from sepsis, with many measurements taken at a minimum of 24 hour intervals23. To more closely profile plasma 
HMGB1 levels in patients during the early phase of septic shock, 17 patients admitted to the intensive care unit 
(ICU) were enrolled in an observational study where arterial blood was sampled twice daily for the duration of 
septic shock. Patient characteristics are summarised in Table 1; patients had a median age of 61 and the majority 
presented with respiratory (35%) or gastrointestinal (29%) sepsis. The age of surviving and non-surviving patients 
was not significantly different.
Patients were assigned an acute physiology and chronic health evaluation (APACHE) II sickness severity score 
within 24 hours of admission to ICU, and kinetic plasma samples taken as described. Non-surviving patients 
exhibited a significantly higher APACHE II score than surviving patients (Fig. 1A), with HMGB1 levels pos-
itively correlated with APACHE II score (Fig. 1B) at 24 hours. Non-survivors also exhibited significantly ele-
vated HMGB1 concentrations overall, with differences most pronounced 24–48 hours after admission, where 
HMGB1 levels were almost threefold higher in non-surviving patients (2.58 ± 0.76 vs 6.04 ± 2.58 in survivors 
and non-survivors, respectively; Fig. 1C).
An exacerbated pro-inflammatory cytokine profile is associated with increased plasma HMGB1 
and non-survival during septic shock. In order to define the cytokine profiles within the septic shock 
cohort, individual plasma samples were subjected to multiplex cytokine analysis. Assessment of results revealed 
consistently elevated IL-1RA, IL-6, IL-8 and MCP-1 in septic shock patients compared to published healthy 
cohorts24, with non-survivors exhibiting significantly lower plasma IL-1RA, IL-6 and IL-10, and increased MCP-1 
levels compared to survivors (Fig. 2A). Both MCP-1 and IL-1RA were almost two-fold higher in survivors com-
pared to non-survivors in the first 48 hours, with IL-10 also consistently higher in survivors. Notably, IL-6 was 
Characteristic Total (n = 17) Survivors (n = 9) Non Survivors (n = 8)
Agea 61 (47–68) 55 (45–65) 64.5 (49–77)
Gender 11 female (64%) 7 female (77%) 4 female (50%)
APACHE II Scorea 18 (15–26.5) 18 (13.5–18.5) 26.5 (16.3–34.8)
Site of infection
 Lung 6 (35.3%) 3 (33.3%) 3 (37.5%)
 Gastrointestinal 5 (29.4%) 3 (33.3%) 2 (25%)
 Skin 4 (23.5%) 2 (22.2%) 2 (25%)
 Other 2 (11.8%) 1 (11.1%) 1 (12.5%)
Positive culture 12 (70.5%) 6 (66.6%) 6 (75%)
 G+ 3 (17.6%) 1 (11.1%) 2 (25%)
 G− 3 (17.6%) 2 (22.2%) 1 (12.5%)
 Fungal 1 (5.8%) 0 1 (12.5%)
 Mixed 5 (29.4%) 3 (33.3%) 2 (25%)
Table 1. Patient cohort characteristics. Unless otherwise stated, data has been represented as: number of 
patients (percentage of n). aData represents median (interquartile range).
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five-fold higher in survivors on day 1 compared to non-survivors. Consistent with previous studies, concentra-
tions of TNFα and IL-1β were highest on day 1 in both groups before declining.
The variable efficacy of previously trialled immune modulating therapies such as anti-TNFα has been linked 
to variations in the inflammatory profile of patients25. Thus, clinical targeting of HMGB1 should be informed by 
analysis of HMGB1 in the context of the septic inflammatory state. In order to evaluate overall inflammatory pro-
files within the septic shock cohort, composite cytokine scores (CCS) were calculated3. Survivors exhibited sig-
nificantly higher total CCS which decreased over time, while non-survivors exhibited lower total CCS (Fig. 2B). 
Calculated ratios of pro-inflammatory (IL-6, MCP-1, IFNγ, TNFα, IL-1β, IL-5 and IL-8) to anti-inflammatory 
(IL-10, IL-4 and IL-1RA) cytokines were significantly higher in plasma samples with elevated HMGB1 (>2.5ng/
mL, the median HMGB1 value in analysed samples) compared to those with reduced HMGB1 (Fig. 2C). 
Furthermore, a significant decrease was observed in inflammatory CCS in survivors compared to non-survivors 
(Fig. 2D). No individual cytokine significantly correlated with HMGB1 content.
Ovine anti-HMGB1 pAb therapy improves survival in an in vivo model of murine endotoxae-
mia. As elevated HMGB1 levels were associated with poor clinical outcomes and dysregulated inflamma-
tory profiles in human patients, a passive immunotherapeutic approach to block HMGB1 was developed and 
assessed for impact on survival in three murine sepsis models of increasing complexity. Firstly, purified ovine 
anti-HMGB1 polyclonal antibodies (pAb) were generated26 and applied to a simple model of sepsis, lethal endo-
toxaemia. Mice that received anti-HMGB1 pAbs one hour prior to LPS administration (prophylactic) exhibited 
a significant survival advantage compared to controls, with a survival rate >70% (Fig. 3A). Groups that received 
either prophylactic control pAb or PBS displayed expected sickness symptoms and typically required euthana-
sia within twenty-four hours. In contrast, mice given prophylactic anti-HMGB1 pAbs exhibited significantly 
fewer symptoms than controls, including surviving mice from the PBS control group (Fig. 3C). Similarly, a trend 
towards increased survival was observed in anti-HMGB1 pAb-treated mice one hour after LPS administration, 
with 30% not requiring euthanasia within the experimental period (Fig. 3B). This lower survival rate was evi-
denced by an increase in the mean clinical score compared to those mice that received prophylactic administra-
tion of pAbs (Fig. 3D). Taken together, these results suggest that ovine anti-HMGB1 pAb can increase survival 
from acute and rapid severe systemic inflammation induced by LPS in this lethal and highly artificial model of 
sepsis.
Ovine anti-HMGB1 pAb-treatment improves survival from CLP sepsis. While sudden endotoxae-
mia is a useful model for acute systemic inflammation, sepsis induced by caecal ligation and puncture (CLP) more 
accurately mimics human sepsis caused by a central focus of infection. It is considered the gold-standard rodent 
sepsis model as the perforated portion of the caecum forms a necrotic mass within the peritoneal cavity and 
intermittently releases bacteria27. This results in a prolonged period of bacterial challenge, and thus inflammatory 
cytokine release. A CLP procedure that resulted in 60–70% mortality was developed to assess the therapeutic 
administration of ovine anti-HMGB1 pAbs. Analysis of serum obtained from mice subjected to CLP or sham 
Figure 1. Plasma HMGB1 concentrations and disease severity and mortality in patients with septic shock. 
Plasma samples from ICU patients with diagnoses consistent with septic shock were taken twice daily (morning 
and afternoon) for the length of ICU stay. (A) APACHE II scores in survivors and non-survivors were compared 
via two-tailed t test. (B) HMGB1 was quantified in patient samples by ELISA and regression analyses performed 
to compare plasma HMGB1 at 24 hours post ICU admission and APACHE II score. (C) Mean kinetic plasma 
HMGB1 levels in survivors versus non-survivors were compared by paired two-way t-test. Significance is 
denoted as thus: *P < 0.05, **P < 0.01.
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surgery (laparotomy only) indicated that the CLP procedure significantly elevated circulating HMGB1 levels at 
24hrs, with levels declining thereafter (Fig. 4A). Groups of mice administered PBS or control pAb 8 hours follow-
ing CLP surgery displayed expected range of symptoms of ill health (hunched posture, ruffled fur, a reluctance to 
move and weight loss) which were not exhibited by mice undergoing sham surgery (Fig. 4B). Mice treated with 
anti-HMGB1 pAbs 8 hours after CLP exhibited consistently lower mean clinical scores compared to PBS-treated 
mice. Overall weight loss was significantly reduced in anti-HMGB1 pAb-treated groups compared to control 
Ab-treated groups (Fig. 4C), and together with improved clinical score, resulted in significantly increased survival 
(Fig. 4D). Collectively, these results indicated that therapeutic anti-HMGB1 pAb treatment can treat septic mice 
and promote recovery from clinical symptoms to increase survival.
Ovine anti-HMGB1 pAb-treated mice display cytokine profiles associated with improved clin-
ical outcomes in the early phase of CLP sepsis. In order to determine the effect of HMGB1 neutrali-
sation on the inflammatory profile in CLP-induced sepsis, serum samples were obtained on day 1, 3, and 7 post 
surgery and assessed for levels of pro- and anti-inflammatory cytokines. Induction of sepsis by CLP resulted in 
early 1.5–20-fold increases in IL-6, IL-10, IFNγ and TNFα over that induced by sham surgery. Treatment with 
anti-HMGB1 pAbs 8 hours post-surgery resulted in a further significant five-fold increase in IL-6 and a four-fold 
increase in IL-10 in anti-HMGB1 mice at day 1 after CLP compared to groups that received PBS or isotype con-
trol pAbs (Fig. 5A). Additionally, cytokine expression in anti-HMGB1 pAb treated animals displayed a delayed 
response, with reduced levels of IL-2 IL-4, IL-12 and IL-13 observed 1 day after CLP compared to controls. These 
cytokine levels then increased to control group day 1 levels by day 3, and diminished thereafter. Pro-inflammator
y:anti-inflammatory CCS calculated for the panel of cytokines tested were not significantly altered between 
groups (Fig. 5B). These data indicate that anti-HMGB1 pAb treatment altered the early-phase inflammatory 
response generated by CLP-induced sepsis, which ultimately improved survival.
Figure 2. Mortality and elevated HMGB1 are associated with a proinflammatory serum cytokine profile in 
a cohort of septic shock patients. Plasma samples from septic shock patients were stored and analysed via 
multiplex analysis. A panel of cytokines (IL-6, MCP-1, IL-10, IFNγ, TNFα, IL-1β, IL-4, IL-5, IL-8 and IL-
1RA) was assessed and concentrations calculated from samples run in duplicate. (A) Plasma concentrations 
of individual cytokines between survivors (black) and non-survivors (grey) were compared via paired t-test. 
Cytokine measurements normalised to the median concentration were used to determine composite cytokine 
scores (CCS). (B) Total CCS indicating the total magnitude of cytokine levels was calculated by summation 
of all ten normalised cytokine scores and compared between survivors and non-survivors. The ratio of pro-
inflammatory (IL-6, MCP-1, IFNγ, TNFα, IL-1β, IL-5 and IL-8) to anti-inflammatory (IL-10, IL-4 and IL-1RA) 
signalling was compared between samples with a low and high HMGB1 content (C) and between survivors 
and non-survivors (D). Plasma cytokine concentrations and ratio between survivors and non-survivors were 
compared via paired t-test and low vs high HMGB1 content samples were compared via unpaired t-test. Data 
are depicted as mean ± SEM, with significance is denoted as thus: *P < 0.05, **P < 0.01.
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Ovine anti-HMGB1 pAb-treatment during CLP-induced sepsis reduces susceptibility to second-
ary P. aeruginosa infection. While anti-HMGB1 pAb treatment increased survival in the short term after 
CLP, it was necessary to determine if surviving mice exhibited post-septic immunosuppression. In order to assess 
susceptibility of mice to a secondary infection, a modified CLP procedure which induced weight loss and 30% 
lethality by day 3 was performed. Survivors subsequently received an intranasal challenge with live P. aerugi-
nosa. Mice subjected to initial sham-surgery exhibited transient weight loss after surgery and mild symptoms 
of infection after bacterial challenge (Fig. 6A), with only 1/6 not surviving (Fig. 6B). In contrast, septic PBS or 
isotype control pAb-treated mice exhibited sharp clinical decline, including weight loss, after bacterial challenge 
(Fig. 6A). The majority reached predetermined humane endpoints within 12–48 hours (Fig. 6B) clearly indicating 
an inability to control a secondary infection. Treatment of CLP-induced sepsis with anti-HMGB1 pAb however, 
left these mice with significantly higher survival rates after secondary bacterial challenge than either control 
groups (Fig. 6B). Whilst weight loss in this group was not significantly different from controls, anti-HMGB1 
pAb-treated mice returned to normal weight earlier than survivors from untreated groups, suggestive of a faster 
time to recovery following bacterial challenge (Fig. 6A).
To assess the effect of anti-HMGB1 pAb therapy on IL-6, IL-10, TNFα and IL-12 cytokine profiles in this sec-
ondary challenge model, blood samples were taken immediately prior to administration of P. aeruginosa on day 
4, and then again, 24 hours later. No significant difference in IL-6, IL-10 or TNFα concentrations between pre- 
and post-challenge samples in either pAb-treated group was observed; however anti-HMGB1 pAb-treated mice 
exhibited a significant increase in IL-12 serum concentration post-challenge which was not observed in control 
pAb-treated mice (Fig. 6C). Analysis of cytokine expression pre- and post-challenge between groups via two-way 
matched-pairs ANOVA revealed that anti-HMGB1 pAb-treatment significantly altered IL-6 and IL-12 responses 
to bacterial challenge. Taken together, these results suggest anti-HMGB1 pAb treatment improves survival from 
secondary infection following CLP-induced sepsis, potentially via alterations in cytokine responses.
Anti-HMGB1 pAb-treatment during CLP-induced sepsis alters macrophage and dendritic cell 
cytokine expression profiles in surviving mice. The increased susceptibility of sepsis survivors to sec-
ondary infection has been linked to post-septic immunosuppression characterised by functional exhaustion of 
lymphocytes, immune cell apoptosis and epigenetic changes within immune cells, including macrophages. Two 
distinct subsets of macrophages with differential capacity to respond to stimuli exist within the peritoneum. 
Large peritoneal macrophages (LPM) are most abundant at resting state and perform roles in homeostasis and 
maintenance28, while small peritoneal macrophages (SPM) rapidly accumulate in the peritoneum following an 
inflammatory stimulus29, and are implicated in conferring inflammatory function in disease29, 30. To investigate 
the effect of anti-HMGB1 pAb treatment on the peritoneal macrophage population during sepsis, peritoneal cells 
were harvested from treated and untreated mice 4 days after CLP-induced sepsis. Flow cytometric analysis was 
performed to determine the frequency of LPM (CD11bhi, F4/80hi, Gr-1+) and SPM (CD11blo, F4/80lo, Gr-1−) in 
Figure 3. Ovine anti-HMGB1 pAb therapy improves survival in an in vivo model of murine endotoxaemia. 
Adult male and female B6 mice were prophylactically administered 20 mg/kg anti-HMGB1 pAb (n = 7), control 
pAb (n = 7) or PBS (n = 7) via IP injection one hour before IP injection of 20 mg/kg LPS (A&C). In a therapeutic 
model, mice were administered 20 mg/kg anti-HMGB1 pAb (n = 6), control pAb (n = 4) or PBS (n = 7) one 
hour after LPS administration (B&D). Experimental mice were monitored over twenty-four hours for clinical 
score and euthanised if predetermined humane endpoints were reached. Survival (A,B) and mean clinical 
score (C,D) of groups is represented. Survival curves were compared to controls using the Mantel-Cox test 
and clinical score data compared to PBS control via two-way ANOVA, with significance denoted as: *P < 0.05, 
**P < 0.01.
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the peritoneal compartment (Fig. 7A). The frequency of LPM was highest in normal mice not subjected to sur-
gery, with all CLP groups regardless of treatment exhibiting significantly lower total numbers of LPM. In contrast, 
an increase in SPM numbers was observed only in CLP groups treated with PBS or isotype control pAb, with 
anti-HMGB1 pAb treated mice harbouring numbers of SPM equivalent to that observed in normal mice, sug-
gesting that neutralisation of HMGB1 inhibited the influx of inflammatory macrophages to the peritoneal cavity.
To determine whether the macrophage populations present 4 days after sepsis induction exhibited altered 
functional responses, peritoneal macrophages were harvested 4 days after induction of sepsis, stimulated with 
LPS ex vivo for 18 hours and supernatant analysed for IL-6, TNFα, IL-10 and IL-12. It was clear that anti-HMGB1 
treatment of septic mice resulted in macrophages that expressed levels and patterns of cytokines that were more 
similar to that expressed by peritoneal macrophages obtained from normal mice than macrophages from either 
PBS or isotype control pAb treated septic mice (Fig. 7B).
Susceptibility to P. aeruginosa following CLP-induced sepsis has been linked to reduced IL-12 and increased 
IL-10 production by dendritic cells (DCs). Therefore, to determine if anti-HMGB1 pAb treatment impacted DC 
function, bone marrow derived dendritic cells (BMDCs) were generated from sham-surgery, PBS treated, control 
pAb-treated or anti-HMGB1 pAb-treated mice four days after CLP-surgery. After 7 days culture in the presence of 
GM-CSF, semi-adherent BMDCs were stimulated with LPS and assayed for IL-10 and IL-12 production. Though 
IL-12 production was not significantly different between treatment groups, results clearly indicated that BMDC 
generated from anti-HMGB1 treated mice secreted a similar amount of IL-10 to that observed from sham surgery, 
non-septic mice, which suggested that neutralising HMGB1 in the context of an initial inflammatory response 
can alter subsequent responses.
Figure 4. Therapeutic administration of ovine anti-HMGB1 pAb improves survival from CLP sepsis. Mice 
were subjected to sham-surgery alone (n = 4) or CLP surgery (n = 4) and serum samples from sham or CLP-
surgery mice were assayed for HMGB1 via ELISA (A). CLP mice (n = 9–11) were administered PBS, control 
antibody or anti-HMGB1 pAb (25 mg/kg) via IP injection eight hours following surgery. Mice were monitored 
and euthanised if predetermined humane endpoints were reached. Mean ± SEM of clinical score (B) and weight 
(C) and survival curves of the groups (D) are depicted. Sequential measurements were compared via two-way 
ANOVA and survival of anti-HMGB1 treated mice was compared to control groups using the Mantel Cox test 
with significance denoted as: *P > 0.05, a*P > 0.05 compared against PBS control, b*P > 0.05 compared against 
control Ab.
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Figure 5. Ovine anti-HMGB1 pAb-treated mice display cytokine profiles associated with improved clinical 
outcomes in the early phase of CLP-induced sepsis. Blood samples from mice (n = 3–5) subjected to sham-
surgery (pale grey area) or CLP-induced sepsis and treated with PBS (unfilled symbols), control pAb (25 mg/
kg; black symbols) or anti-HMGB1 pAb (25 mg/kg; grey symbols) were analysed for cytokine content using a 
multiplex platform. Mean + SEM of individual cytokine measurements are depicted. (A). Proinflammatory (IL-
2, IL-5, IL-6, IL-12, IFNγ, GM-CSF and TNFα) to anti-inflammatory (IL-4, IL-10 & IL-13) CCS were calculated 
for each sample, mean + SEM group CCS normalised to median values are depicted in (B). Levels of cytokines 
were compared using two-tailed T-tests, with significance denoted as thus: *P < 0.05.
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Discussion
Clinical and preclinical studies have implicated HMGB1 as a mediator of sepsis pathogenesis and mortality, and 
thus HMGB1 represents a novel candidate for passive immune targeting in sepsis. Our studies presented here 
indicate that administration of anti-HMGB1 pAb to a murine model of severe sepsis alters the pattern of cytokine 
signalling to a more favourable profile, improves survival, and protects against the development of post-septic 
immunosuppression. The association between plasma HMGB1 and morbidity and mortality within the septic 
shock patient cohort is consistent with findings from several previous studies where HMGB1 was found to be 
elevated in patients with more severe illness31–34. A 2008 study of severe sepsis patients revealed a significant 
correlation of plasma HMGB1 with SOFA score in the most severely ill subgroup of patients, however HMGB1 
Figure 6. Prior anti-HMGB1 pAb treatment alters the inflammatory response and survival to secondary 
bacterial challenge in mice that have survived CLP-induced sepsis. Mice (n = 6–12) were subjected to sham-
surgery or mild CLP and allowed to recover before IN instillation of P. aeruginosa (2.5 × 107 CFU) or PBS on 
Day 4 (indicated by dashed line). Mice were treated 8 hours following surgery with anti-HMGB1 or control 
pAbs (20 mg/kg) or PBS and administered maintenance pAb doses (10 mg/kg) or PBS on days 3 and 6. Mice 
were monitored for disease symptoms and euthanised at predetermined humane endpoints. Mean - SEM 
weight loss (A; humane weight loss endpoint indicated by horizontal dashed line) and survival (B) and of 
mice are depicted. Serum samples collected from mice (n = 4–5) immediately prior to bacterial challenge and 
24 hours after challenge were analysed for IL-6, IL-10, IL-12 or TNFα content via ELISA (C). Survival curves 
were compared via Mantel-Cox analysis, and changes in cytokines before and after treatment were compared 
via paired t-test. Cytokine changes between groups were compared via two-way matched pairs ANOVA, with 
significance denoted as thus: *P < 0.05, **P < 0.01.
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was not found to be different between all survivors and non-survivors within the cohort35. An earlier study had 
demonstrated a significant decrease in plasma HMGB1 in non-survivors using a western-blot method however 
this result was not recapitulated using an alternate western-blot protocol23. In the current study, HMGB1-specific 
ELISA was employed to measure patient and murine samples. It has been postulated that while ELISA may be a 
more sensitive method for detection of plasma biomarkers, HMGB1 binding proteins or other masking factors 
may complicate HMGB1 detection in these assays23, 34. Consequently, further studies are required to determine 
the most useful method to effectively measure bioavailable HMGB1.
Individual plasma cytokine levels are not considered good prognostic indicators in clinical practice due to the 
inherent variability seen in sepsis36, 37, however as expected the concentrations of several cytokines were different 
between survivors and non-survivors. For example, IL-6 was higher in survivors, a finding at odds with previous 
studies38, although in a manner similar to this study, elevated IL-6 levels in the first 48 hours from sepsis onset 
Figure 7. Anti-HMGB1 pAb treatment alters macrophage and DC cytokine expression post survival from 
CLP-induced sepsis. Peritoneal cells were harvested four days following CLP surgery and treatment with 
either PBS (n = 4), control ovine pAb (n = 4) or anti-HMGB1 pAb (n = 5) and evaluated via flow cytometry. 
Frequency of large peritoneal macrophages (LPM; CD11bhi, F4/80hi, Gr-1+) and small peritoneal macrophages 
(SPM; CD11blo, F4/80lo, Gr-1−) compared to normal mice (n = 2) are expressed (A; Mean + SEM). Adherent 
macrophages from peritoneal lavages were stimulated with LPS (100 ng/mL) for 18 hours and IL-6, IL-10, IL-12 
and TNFα content in the supernatant was evaluated via ELISA. Mean + SEM expression for each treatment 
relative to unstimulated wells is expressed (B). Bone marrow cells harvested from Day 4 septic or sham-surgery 
mice were cultured in the presence of GM-CSF to generate bone-marrow derived dendritic cells (BMDCs). 
Harvested BMDC’s were plated and cultured in the presence of LPS (100 ng/mL); Mean + SEM IL-10 and IL-12 
cytokine content of resulting supernatants is expressed (C). Mean values of individual groups were compared 
via two-tailed t tests, with significance denoted as thus: **P < 0.01, *P < 0.05.
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in survivors has also been reported39. Importantly, only septic shock patients were sampled within the current 
study, which comprise a unique sub-population within sepsis patients. Non-survivors exhibited rapid increases 
in IL-4 and IL-1RA from day 2, and concurrent pro-inflammatory increases in TNFα and IL-1β which were not 
statistically significant. The profile of overall cytokine release may be a more valuable measurement than individ-
ual cytokine concentrations. Hence in this study, cytokine measurements were used to calculate pro-inflammator
y:anti-inflammatory ratios for each sample. Non-survivors had significantly increased pro-inflammatory capac-
ity which also increased over time compared to survivors. Increased plasma HMGB1 was also associated with 
an enhanced pro-inflammatory profile supporting the notion of HMGB1 as a pro-inflammatory cytokine. 
Non-survivors exhibited reduced overall cytokine signalling over the sampling period. Together, these obser-
vations may indicate that non-survivors are not able to balance early pro-inflammatory signalling leading to 
increased pathology and lethality. Additionally, measured concentrations of anti-inflammatory cytokines IL-4, 
IL-10 and IL-1RA increased at later time points in the surviving cohort, which may indicate effective regulation 
of inflammation. The timeframe of sampling in this study was too short to deduce long-term signalling patterns, 
however it can be speculated that assessment of HMGB1 concentration and pro-inflammatory:anti-inflammatory 
cytokine ratio may aid in monitoring clinical course. The broader availability of efficient multiplexed plasma anal-
ysis technology simplifies the monitoring of these parameters in a clinical setting.
The observations from the patient study support development of a septic shock treatment targeting HMGB1. 
It was hypothesised that HMGB1 blockade may be more efficacious in the clinic than targeting pro-inflammatory 
cytokines, as HMGB1 exhibits both pro-inflammatory and anti-inflammatory activities and has a wider thera-
peutic window11, 22. In a short-term model of murine endotoxaemia, anti-HMGB1 pAb administration increased 
survival when administered prophylactically, providing proof-of-principal that anti-HMGB1 pAb could reduce 
inflammation in vivo. As an example of a more complex septic disease, the impact of anti-HMGB1 pAb on septic 
inflammatory profile was assessed in the CLP model. Mice subjected to CLP-surgery had significantly higher 
serum HMGB1 than sham-surgery controls, though HMGB1 release was earlier and more transient than in 
patient groups, which may reflect the kinetics of sepsis induced by CLP. Anti-HMGB1 pAb treatment increased 
survival in this model compared to control groups. Treated mice also had fewer clinical signs of disease and 
reduced weight loss than control groups, indicating that HMGB1 blockade reduced morbidity and mortality 
from CLP sepsis, a result in agreement with previous studies40, 41. Analysis of cytokine profiles following treatment 
revealed significant elevations in IL-6 and IL-10 in anti-HMGB1 pAb-treated mice 24 hours following surgery, 
which were both associated with survival in the septic shock patient cohort. Previous studies have implicated 
IL-10 as an important regulator of early inflammation which delays the onset of septic shock9. In the context of 
the current findings, the observed increase in IL-10 in survivors and anti-HMGB1 pAb-treated mice may serve to 
modulate early pro-inflammatory pathways and reduce lethality.
Patients that survive the early inflammatory phase of sepsis may become immunosuppressed and contract sec-
ondary infections. While anti-HMGB1 pAb therapy increased survival in simple endotoxaemia and CLP sepsis, 
it was unknown whether anti-HMGB1 could potentiate immunosuppression and increased susceptibility to sec-
ondary infection. To investigate this, a ‘double-hit’ model of CLP-induced sepsis followed by bacterial challenge 
was employed, where sepsis survivors exhibit increased susceptibility to Pseudomonas challenge42. Anti-HMGB1 
pAb-treated septic mice had a survival advantage compared to control mice following secondary infection 
and treatment was associated with improved antimicrobial responses as mice exhibited increased IL-12 and 
decreased IL-6 following infection. As post-septic immunosuppression is associated with altered innate immune 
cell function43, 44, macrophages in the peritoneal cavity from CLP mice were evaluated at day 4 following CLP. 
Anti-HMGB1 pAb-treated mice exhibited decreased numbers of SPMs within the peritoneal cavity, which may 
be a result of a less severe disease course as SPMs migrate to the peritoneal cavity in response to inflammatory 
challenge28. Importantly, peritoneal macrophages from anti-HMGB1 pAb-treated mice displayed significantly 
decreased IL-6 and increased IL-12 expression after in vitro LPS stimulation compared to controls. Recently, DC 
dysfunction has been implicated in the double-hit model where reduced IL-12 and increased IL-10 production 
promote susceptibility to secondary infection45. Here, BMDC generated from anti-HMGB1 pAb-treated CLP 
mice expressed lower quantities of anti-inflammatory IL-10 when compared to BMDC from untreated mice 
indicating that the immunosuppressive phenotype of dendritic cells was altered by HMGB1 inhibition, however 
no such differences were observed for IL-12.
While the role of HMGB1 in the development of immunosuppression and immunoparalysis in sepsis is poorly 
understood, several potential mechanisms have been described that may contribute to the results described here. 
The observed phenotype of peritoneal macrophages from septic mice likely represents a partial tolerance to 
LPS, as it has been shown that HMGB1 directly induces LPS tolerance in macrophages46, in addition to other 
pro-inflammatory cytokines. Thus, the observed effect of anti-HMGB1 pAb treatment on macrophage function 
may be mediated by both direct blockade of HMGB1 signalling on macrophages, and by an altered inflamma-
tory milieu. As the administration of ‘naïve’ DCs can reverse post-septic disease susceptibility in the double-hit 
model47, DC function is clearly central to the development of septic immunosuppression. In the current study, 
anti-HMGB1 pAb treatment altered the response of BMDCs to LPS stimulation with less IL-10 secreted after LPS 
stimulation than from BMDCs derived from untreated septic mice. While HMGB1 is necessary for DC matura-
tion48, excessive HMGB1 release may contribute to abnormal maturation of DCs to promote Th2 responses49 and 
consequently anti-HMGB1 pAb may alter DC function by interfering with these pathways.
It has been shown here that anti-HMGB1 pAb are efficacious in experimental sepsis, they alter inflam-
matory profiles associated with clinical lethality and do not promote immunosuppression. Though many 
immune-modulating therapies have been trialled in sepsis, none have exhibited significant clinical benefit over 
current standard-of-care50. In this study, inflammatory profiles in patients were heterogeneous, thus a more effec-
tive approach to treating sepsis may involve delivering therapies reflective of their immune status. Therapies that 
target master immune regulators could serve to first reduce the severity of cytokine deregulation in early sepsis 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7: 5850  | DOI:10.1038/s41598-017-06205-z
before targeting specific pro- or anti- inflammatory cytokines to reverse pathogenic immune signalling. As such, 
HMGB1-blockade may aid in dampening the magnitude of inflammatory signalling in sepsis and leave patients 
more responsive to further therapeutic immunomodulation. These results demonstrate that HMGB1 targeted 
therapeutics offer potential for further development for the treatment of clinical sepsis and septic shock.
Methods
Ethics statement. Human studies were approved by the Royal Adelaide Hospital Research Ethics 
Committee and accepted by The University of Adelaide and University of South Australia Human Research Ethics 
Committees under the National Mutual Acceptance system. All procedures relating to the enrolment, sampling 
and analysis of patients conformed to the provisions of the National Statement on Ethical Conduct in Human 
Research (2007), Australian National Health and Medical Research Council, with informed consent obtained 
from all participants or next of kin.
All animal studies were conducted with dual approval from The University of Adelaide Animal Ethics 
Committee, and the University of South Australia Animal Ethics Committee, and followed institutional and 
national ethical guidelines according to the principles outlined in the ‘Australian code for the care and use of 
animals for scientific purposes (2013)’.
Patient recruitment and clinical study. To profile the presence of serum HMGB1 in patients during 
the early phase of septic shock, a prospective cohort study was performed on septic shock patients admitted to 
the Royal Adelaide Hospital (RAH) ICU for a one year period (December 2012 - December 2013). Consecutive 
patients ≥18 years old admitted to the ICU with septic shock were identified by clinical staff, with septic shock 
defined as a diagnosis consistent with sepsis (including pneumonia, urinary tract infection and peritonitis) in 
addition to hypotension (MAP < 70 mmHg) despite adequate fluid resuscitation (>500 mL fluid administered), 
adequate intravascular volume status (Pulmonary arterial wedge pressure >12 mmHg or Central Venous Pressure 
>8 mmHg) and the need for vasopressors. Vasopressors included any infusion of noradrenalin and/or adrenalin. 
Informed consent was sought from patients or next-of-kin as appropriate, and all samples obtained from patients 
were de-identified prior to storage and analysis. Patients on steroid therapy were excluded from the study, with 
the remaining patient cohort characteristics summarised in Table 1. Arterial blood was collected from patients 
into sodium citrate tubes on the first morning after admission (1–12 hours post admission) and every morning 
and afternoon thereafter for as long as haemodynamic intervention was required or a maximum of 7 days. Blood 
samples were centrifuged (10 minutes, 1,000 × g) and the plasma aliquoted and frozen (−80 °C). Plasma samples 
were analysed for HMGB1 content by ELISA (Shino-Test, IBL) according to manufacturer’s instructions, with 
samples diluted 1 in 2 in assay buffer and a standard curve ranging from 80 ng/ml to 300 pg/ml.
Ovine polyclonal anti-HMGB1 production. Ovine anti-HMGB1 polyclonal antibodies (pAbs) were gen-
erated via immunisation of sheep with purified recombinant HMGB1 in Freund’s adjuvant and purified as previ-
ously described26. Total anti-HMGB1 and control IgG was purified via Protein G chromatography. Purified pAbs 
were buffer exchanged to PBS and sterile filtered through a 0.22 µm membrane before freezing in concentrated 
stocks (5–10 mg/ml). Ovine anti-HMGB1 pAbs were evaluated in vitro and in vivo as previously described26.
Endotoxin model of toxic shock. Endotoxaemia was induced in 6–8 week old C57Bl/6 mice by IP injec-
tion of 20 mg/kg 0111:B4 LPS (Sigma) which caused all animals to reach humane endpoints requiring euthanasia 
in 12–18 hours. Animals were monitored for signs of toxicity including hunched posture (score 0–2), ruffled coat 
(score 0–2), diarrhoea (score 0–2), dehydrated eyes (score 0–2), reduced temperature (score 0–1) and reluctance 
to move (score 0–2) and a cumulative clinical score of 6 or above indicated a requirement for euthanasia. Ovine 
pAbs (25 mg/kg) or PBS were administered via IP injection either one hour before (prophylactic) or one hour 
after (therapeutic) LPS administration. The dose of pAbs was determined from empirical trials reported in pre-
vious studies26.
Caecal ligation and puncture (CLP) model of sepsis. Aged male 10–12 week old C57Bl/6 mice were 
weighed, anaesthetised via isoflurane inhalation and their abdomen shaved and disinfected with Betadine solu-
tion. Caecal ligation and puncture (CLP) surgery was performed as previously described51. Briefly, 7 mm of the 
tip of the caecum was ligated using 4.0 silk sutures and the tip pierced twice with a 21G needle to produce two 
punctures. The laparotomy was closed using 4.0 silk sutures and the outer skin closed with 6.0 prolene sutures. 
Mice were administered subcutaneous Buprenorphine (0.05 mg/kg), Enrofloxacin (5 mg/kg) and saline (1 mL) 
and allowed to recover from anaesthetic in a pre-warmed cage before transfer to individual cages. Mice were 
monitored 1–3 times daily for signs of clinical disease and euthanised upon reaching pre-determined humane 
endpoints, which included a clinical score of 5 or 20% weight loss from surgery day. Mice were injected with 
saline (1 mL; SC) and provided with moistened food daily. This protocol resulted in >60% of mice reaching 
humane endpoints requiring euthanasia and is considered a septic syndrome of moderate severity. Treatment 
with anti-HMGB1 or control pAb (25 mg/kg), or saline was performed 8 hours following surgery to randomly 
selected mice via intraperitoneal injection. Blood samples for cytokine analysis were obtained on day 1, 3 and 7 
post surgery from experimental groups via facial vein bleeds.
Microbiologic preparation and double-hit sepsis model. To determine if treated mice exhibited 
reduced post-septic immunosuppression, treated and untreated mice were subjected to a less severe one-puncture 
CLP surgery and challenged with live Pseudomonas aeruginosa four days later. A single bacterial colony grown 
from a frozen stock of P. aeruginosa (ATCC 27853) was suspended in fresh TSB and grown overnight at 35 °C 
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with constant shaking. Bacteria pelleted from the broth culture were washed and resuspended in PBS and 
adjusted to an optical density of 0.5 A600nm as measured on a spectrophotometer. A colony count of ~1 × 109 CFU/
mL was confirmed with serial dilution onto TSB agar. Aged male 10–12 week old C57Bl/6 mice were subjected to 
sham surgery or a modified CLP procedure, where a 5 mm section of caecum was ligated and only one puncture 
was performed with a 23 G needle. Supportive medications were provided and monitoring was performed as 
described above and anti-HMGB1 pAbs or control treatments (25 mg/kg) were administered 8 hours following 
surgery and every 3 days for the duration of the study. On day 4, 96 hours after modified CLP surgery, P. aerug-
inosa inoculum (25 µL) was administered via intranasal inhalation under anaesthesia. Mice were monitored as 
above and euthanised according to pre-determined humane endpoints. For cytokine analysis before and after 
bacterial challenge, a separate cohort was subjected to modified CLP and bled pre-challenge on day 4 via facial 
vein bleed, and post-challenge via terminal bleed; these mice were not included in survival analysis.
Isolation and stimulation of peritoneal macrophages. Peritoneal lavage was performed on humanely 
killed mice with 3 × 2.5 mL ice-cold endotoxin free PBS supplemented with 1% fetal calf serum. Peritoneal cells 
were pelleted by centrifugation (300 xg, 5 min) and resuspended in 250 µL red blood cell lysis buffer before 
incubation (5 min, room temperature). Cells were washed twice with warm RPMI medium supplemented with 
10% fetal calf serum, 100 U/mL penicillin and 100 μg/mL gentamycin (cRPMI), and plated at 2 × 105 cells/well 
(400 µL) in duplicate in 48-well plates. Plates were incubated for 90 min at 37 °C 5% CO2 to allow macrophages 
to adhere. Supernatants and non-adherent cells were subsequently removed, and adherent cells washed with 
endotoxin-free PBS before incubation with or without LPS (1 μg/mL) in 250 µL cRPMI for 18 hours. Supernatants 
were subsequently harvested and stored at −20 °C for analysis.
For macrophage analysis of peritoneal lavage cells, cells were washed and stained with Fc Block (anti-CD16/
CD32) (1:100), anti-F4/80 PE (1:100), anti-CD11b AF488 (1:100) and anti-Gr-1-biotin (1:100) with 
streptavidin-APC. Cells were analysed on a three-laser BD FacsCANTO II Flow Cytometer. Doublets were 
excluded by gating on FSC-A/FSC-H, and viable cells were used for analysis.
Generation and stimulation of bone marrow-derived dendritic cells (BMDC). Bone marrows were 
harvested and used to generate BMDC using GM-CSF sourced from B16-GMCSF conditioned medium. Briefly, 
bone marrow was flushed from the tibia and femur bones of B6 mice and homogenised via passage through 19G, 
21G and 23G needle bores and red blood cells were lysed. Resulting bone marrow cells were counted plated at 
a density of 5 × 105 cells/mL and cultured for 7 days in complete RPMI medium supplemented with 10% FBS 
and 10% B16-GMCSF conditioned medium. Media volume was replenished by 50% on Day 3 and Day 5. On 
day 7, lightly adherent DCs were harvested via gentle pipetting and plated in duplicate wells of 48-well-plates at 
2 × 105 cells/mL in the presence of LPS (100 ng/mL). Cell-free supernatants were harvested 18 hours later and 
frozen for cytokine analysis.
Cytokine analysis. Cytokines present in human plasma and mouse serum were analysed via BioPlex 
multiplex platform (BioRad MagPix) according to the manufacturer’s instructions. Cytokines to be measured 
from human plasma were selected from clinical studies of multiplex cytokine analysis in sepsis patients52, 53 and 
included IL-1β, IL-1RA, IL-4, IL-5, IL-6, IL-8, IL-10, interferon gamma (IFNγ), monocyte chemotactic pro-
tein 1 (MCP-1) and TNFα. Measured murine cytokines were based on a Th1/Th2 murine panel and included 
IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), IL-13, IFNγ, GM-CSF and TNFα. All samples were run in duplicate 
using a one-in-five sample dilution and concentrations calculated from a standard curve using Bio-Rad Manager 
MP Software. Composite cytokine scores (CCS) expressing the ratio of pro-inflammatory to anti-inflammatory 
cytokines was calculated based on a previously published method3. Briefly, human cytokine concentrations 
were first normalised to the median measurement and CCS was calculated by dividing the sum of normalised 
pro-inflammatory cytokine values (IL-6, MCP-1, IFNγ, TNFα, IL-1β, IL-5 and IL-8) by the sum of normal-
ised anti-inflammatory cytokine values (IL-10, IL-4 and IL-1RA). Murine CCS were similarly determined using 
proinflammatory cytokine (IL-2, IL-5, IL-6, IL-12, IFNγ, GM-CSF and TNFα) and anti-inflammatory cytokine 
(IL-4, IL-10 & IL-13) expression.
Concentrations of IL-6, IL-10, IL-12 and TNFα in culture supernatants were measured via ELISA using com-
mercially available antibodies (eBioscience).
Statistical analysis. Analysis was performed using GraphPad Prism V3.0 software. Survival curves were 
analysed via Mantel-Cox testing. Sequential measurements over time were compared between groups using 
Two-Way ANOVA and individual time points were compared using two-tailed t-tests, with P < 0.05 considered 
statistically significant.
Availability of data and materials. The datasets collected during the current study are available from the 
corresponding authors on reasonable request.
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